Loading...
•
Dec 31, 2019
Eton Q4 2019 Earnings Report
Eton reported Q4 2019 financial results, marking its transition to a commercial revenue company with the launch of Biorphen.
Key Takeaways
Eton Pharmaceuticals reported revenue of $0.5 million for the fourth quarter of 2019, driven by initial Biorphen stocking orders. The company's net loss for the quarter was $2.7 million. As of December 31, 2019, Eton had cash and cash equivalents of $12.1 million.
Launched Biorphen, the first FDA-approved ready-to-use formulation of phenylephrine injection, in December.
Initial customer demand for Biorphen led to purchases by over 100 institutions.
Entered into a co-promotion arrangement with Xellia Pharmaceuticals for Biorphen.
Submitted the ANDA for DS-300 in December.
Eton
Eton
Forward Guidance
Eton is focused on earning additional product approvals in 2020 and driving customer adoption of Biorphen.